Dysbiosis versus diabesity: Pathological signaling and promising therapeutic strategies

Drug Discov Today. 2023 May;28(5):103558. doi: 10.1016/j.drudis.2023.103558. Epub 2023 Mar 21.

Abstract

A healthy life depends on the inseparable relationship between a host and the gut microbiota. A healthy gut microbiota regulates intestinal integrity, whereas an unbalanced gut microbiota contributes to junctional remodeling and leads to dysbiosis. Bacterial infiltration and dysbiosis are reported to activate a series of pathological cascades that trigger metabolic abnormalities, including diabesity. Conversely, recent studies revealed that the incidence of dysbiosis itself is fuelled by diabesity. In this review, we highlight the molecular aspects of multifaceted pathological signaling between dysbiosis and diabetes that could pave the way for new drug discovery. Moreover, to reinstate the gut microbiota and restrict the epidemic of dysbiosis and diabesity, we also scrutinize a promising therapeutic strategy that can challenge the pathological interlink.

Keywords: diabesity; dysbiosis; gut microbiota; low-grade inflammation; signaling mechanism.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bacteria
  • Dysbiosis*
  • Gastrointestinal Microbiome*
  • Humans
  • Intestines